ClinicalTrials.gg
RecruitingNCT00267501Updated Sep 17, 2025

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

An observational study in Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease and Food Allergy, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Children's Hospital Medical Center, Cincinnati · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Food Hypersensitivity with a site in United States — 19 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.

Planned enrollment
5th of 33
5,000 · median 270
Started
2005
with 1 other
Observational
33 of 139
7 open now
Primary completion
2050-01
later than 27 of 27 live
Registered
3rd of 139
by date

Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 5th largest by planned enrollment of the 33 observational ones that give a count, is one of 2 that started in 2005, is one of 33 observational ones, reaches primary completion later than 27 of the 27 other live ones, and was the 3rd registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

19 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Food Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to elucidate the mechanisms underlying eosinophil growth, survival, migration, and function and to investigate and further characterize the pathophysiology of, clinical manifestations of, and spectrum of disease severity of eosinophilic inflammation in humans.

03

Conditions studied

  • Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease
  • Food Allergy

Keywords

  • Eosinophilic Disorders
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with eosinophilic disorders and patients without eosinophilic disorders to serve as normal controls

Eligibility criteria

Inclusion Criteria:

  • Signed obtained from the patient or parent/guardian. Assent will be obtained from all minors 11 years of age and older.
  • Carrying a diagnosis of eosinophilic gastrointestinal disease, eosinophilic inflammatory disease, or food allergy OR family member, or normal control
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
06

Study locations

1 of 1 sites recruiting
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Jan 2050 and a completion of Jan 2050. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2005
First posted
Dec 21, 2005
Start
May 2005
Primary completionEst.
Jan 2050
CompletionEst.
Jan 2050
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00267501
Responsible party
Sponsor
First posted
Dec 21, 2005
Start date
May 2005
Primary completion
Jan 2050 (estimated)
Completion
Jan 2050 (estimated)
Last update
Sep 17, 2025

Study contacts

Bliss Magella
Contact
bliss.magella@cchmc.org
513-636-7832
Marc E. Rothenberg, M.D., Ph.D.
principal investigator · Cincinnati Children's Hospital Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion